Bicycle Therapeutics Announces Initial Duravelo-2 ASCO Data

What Happened
Bicycle Therapeutics plc (BCYC) filed a Form 8-K on May 21, 2026 (Item 8.01) to announce initial clinical data for its candidate Duravelo-2 in metastatic urothelial cancer, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The company attached a press release with the announcement as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: May 21, 2026 (Form 8-K, Item 8.01).
• Event: Initial Duravelo-2 data for metastatic urothelial cancer presented at ASCO 2026.
• Disclosure: Press release announcing the data is attached as Exhibit 99.1 to the 8-K.
• The 8-K did not report other items such as financial results or executive changes.

Why It Matters
Clinical data releases like this are material for investors because they provide information on the progress and potential of a company’s drug candidates. The ASCO presentation signals development progress for Duravelo-2 in an oncology indication; investors should review the attached press release (Exhibit 99.1) for the detailed data points and any next steps the company discloses.